Testing camizestrant before surgery for early-stage endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called camizestrant, which may block estrogen signals that help endometrial cancer grow. It is given before surgery to see if it can shrink tumors and help people with early-stage, ER-positive endometrial cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older and have been through menopause.
- You have been newly diagnosed with endometrial cancer that is estrogen receptor (ER) positive and is planned to be removed with surgery.
- Your cancer is at an early stage (I–III) and has not spread widely.
- You have not had any prior cancer treatment (chemotherapy, radiation, hormone therapy, or surgery) for this cancer.
- You are generally healthy and can care for yourself (ECOG 0 or 1).
- You are willing to provide tumor and blood samples for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
This trial tests a combination of two drugs (camizestrant and ribociclib) for advanced breast cancer that is hormone-receptor-positive and HER2-negative. The study aims to see if this combination helps patients whose cancer cannot be surgically removed or treated with radiation alone.
This trial tests a combination of a PD-1 inhibitor (a type of immunotherapy) with chemotherapy given before surgery for advanced endometrial cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
This trial looks at better ways to predict how aggressive your endometrial cancer is before surgery, so doctors can decide if they need to check your lymph nodes. It may help tailor your treatment to avoid unnecessary procedures.
Hear when a new Estrogen Receptor-positive trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.